Danaher Corporation $DHR Shares Acquired by Western Wealth Management LLC

Western Wealth Management LLC boosted its position in shares of Danaher Corporation (NYSE:DHR) by 9.6% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 6,368 shares of the conglomerate’s stock after acquiring an additional 556 shares during the quarter. Western Wealth Management LLC’s holdings in Danaher were worth $1,258,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Itau Unibanco Holding S.A. grew its holdings in Danaher by 1,778.8% in the 2nd quarter. Itau Unibanco Holding S.A. now owns 3,457 shares of the conglomerate’s stock valued at $673,000 after buying an additional 3,273 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in shares of Danaher by 0.3% in the 2nd quarter. Kingsview Wealth Management LLC now owns 208,986 shares of the conglomerate’s stock valued at $41,283,000 after buying an additional 627 shares during the period. Cornerstone Advisors LLC increased its stake in Danaher by 207.0% during the second quarter. Cornerstone Advisors LLC now owns 109,600 shares of the conglomerate’s stock worth $21,650,000 after acquiring an additional 73,900 shares during the last quarter. Citizens Financial Group Inc. RI lifted its stake in Danaher by 13.3% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 20,135 shares of the conglomerate’s stock worth $3,978,000 after acquiring an additional 2,361 shares in the last quarter. Finally, Avantax Advisory Services Inc. lifted its holdings in Danaher by 12.4% during the 2nd quarter. Avantax Advisory Services Inc. now owns 49,031 shares of the conglomerate’s stock worth $9,686,000 after buying an additional 5,390 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Evercore ISI increased their price target on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a report on Monday, November 10th. Bank of America decreased their price target on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Redburn Partners set a $220.00 price target on Danaher in a report on Wednesday, October 8th. Finally, Robert W. Baird set a $247.00 target price on shares of Danaher in a research report on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $243.39.

Danaher Price Performance

NYSE:DHR traded down $1.65 during trading hours on Monday, hitting $219.56. The company’s stock had a trading volume of 88,135 shares, compared to its average volume of 4,178,206. The company has a market capitalization of $155.09 billion, a PE ratio of 45.37, a PEG ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The business’s 50-day moving average is $205.63 and its two-hundred day moving average is $201.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the business earned $1.71 earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is 26.39%.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 29,728 shares of company stock valued at $6,448,990. 11.10% of the stock is owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.